These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15626585)

  • 1. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis.
    Fotaki N; Symillides M; Reppas C
    Eur J Pharm Sci; 2005 Jan; 24(1):115-22. PubMed ID: 15626585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
    Duan X; Liu Q; Zhang Y; Bi K; Chen X; Wang Y; Luo G
    Drug Dev Ind Pharm; 2009 Apr; 35(4):499-507. PubMed ID: 18979308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
    Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
    Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
    Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
    Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet.
    Kosoglou T; Kazierad DJ; Schentag JJ; Patrick JE; Heimark L; Radwanski E; Christopher D; Flannery BE; Affrime MB
    J Clin Pharmacol; 1995 Feb; 35(2):151-8. PubMed ID: 7751425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
    Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation.
    Li X; Jiang Q; Du L; Li Y; Li M
    Pharmazie; 2014 Feb; 69(2):109-16. PubMed ID: 24640599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients.
    Kanjanabuch T; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S129-37. PubMed ID: 17044464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release.
    Li X; Jiang Q; Du L; Wang C; Chi Q
    Pharmazie; 2012 Aug; 67(8):695-700. PubMed ID: 22957434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
    Chen J; Jiang XG; Cai L; Lu W; Gao KP; Shi ZQ; Zhang QZ
    Arzneimittelforschung; 2004; 54(4):203-6. PubMed ID: 15146932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms].
    Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G
    Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract.
    Kramer WG
    J Clin Pharmacol; 1994 Dec; 34(12):1218-21. PubMed ID: 7738218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a single oral dose of isorsorbide 5-mononitrate in normal dogs and in dogs with congestive heart failure.
    Adin DB; Kittleson MD; Hornof WJ; Kass PH
    J Vet Intern Med; 2001; 15(2):105-11. PubMed ID: 11300592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers.
    Sawicki W; Deptulski T; Janicki S
    Pharmazie; 1989 Apr; 44(4):280-1. PubMed ID: 2772003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the time to onset of action on myocardial ischaemia following intravenous administration of isosorbide dinitrate and 5-isosorbide mononitrate in Chinese patients.
    Wu ZG; Li JN; Fan M; Shang YK; Zhang YW; Bai J; Ding R; Cheng JM; Liang C
    Arzneimittelforschung; 2004; 54(5):275-9. PubMed ID: 15212189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
    Yang LL; Yuan YS; Zhao FL
    Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
    Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R
    Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on preparation of isosorbide-5-mononitrate pulsatile controlled-release pellets and various influence factors].
    Wang R; Huang G; Fang Z
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Aug; 25(4):885-8. PubMed ID: 18788301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.